FDA begins new drug application review for Liquidia Technologies’ LIQ-861 in pulmonary arterial hypertension

shutterstock_1482976502
If successful, LIQ-861 will have an edge over other already established marketed treprostinil drugs such as United Therapeutics’ Orenitram, Remodulin, and Tyvaso. Credit: Alexsey t17 / Shutterstock.